ConductScience.org, home

Paper36551663

HER3 Alterations in Cancer and Potential Clinical Implications.

Kilroy MK and 6 others. Cancers (Basel), 2022. Cited by 20 papers, by iCite.

Cite this record

ConductScience Library. HER3 Alterations in Cancer and Potential Clinical Implications. Papers, record 36551663. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36551663

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
HER3 Alterations in Cancer and Potential Clinical Implications.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
20
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2022-12-25
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kilroy MKMary Katehttps://orcid.org/0000-0002-2922-4476
2Park SSoYounghttps://orcid.org/0000-0002-1233-1232
3Feroz WWasim
4Patel HHima
5Mishra RRosalinhttps://orcid.org/0000-0002-9808-8797
6Alanazi SSamarhttps://orcid.org/0000-0002-2415-7227
7Garrett JTJoan T

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
1016616American Cancer SocietyPubMed

Source PubMed

Download CSV of grants

References149

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118259690The epidermal growth factor receptor family: biology driving targeted therapeutics.Cell Mol Life Sci2008https://conductscience.org/library/papers/18259690PubMed
229383036Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.Ther Adv Med Oncol2018https://conductscience.org/library/papers/29383036PubMed
332847130Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.Cancers (Basel)2020https://conductscience.org/library/papers/32847130PubMed
425891541Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.Lung Cancer2015https://conductscience.org/library/papers/25891541PubMed
531548545Breast cancer.Nat Rev Dis Primers2019https://conductscience.org/library/papers/31548545PubMed
635625959Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/35625959PubMed
714623113Shc-dependent pathway is redundant but dominant in MAPK cascade activation by EGF receptors: a modeling inference.FEBS Lett2003https://conductscience.org/library/papers/14623113PubMed
824300455HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome.Eur J Cancer2014https://conductscience.org/library/papers/24300455PubMed
926689995Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.Oncotarget2016https://conductscience.org/library/papers/26689995PubMed
1032034073Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.Clin Cancer Res2020https://conductscience.org/library/papers/32034073PubMed
1132080212Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers.Sci Rep2020https://conductscience.org/library/papers/32080212PubMed
1230975923Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.Oncologist2019https://conductscience.org/library/papers/30975923PubMed
1335839938Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer.Radiother Oncol2022https://conductscience.org/library/papers/35839938PubMed
1434320350ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.Cell Rep2021https://conductscience.org/library/papers/34320350PubMed
1510880430The ErbB signaling network: receptor heterodimerization in development and cancer.EMBO J2000https://conductscience.org/library/papers/10880430PubMed
1634548309Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.Cancer Discov2022https://conductscience.org/library/papers/34548309PubMed
1733750895Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer.Oncogene2021https://conductscience.org/library/papers/33750895PubMed
1831519989ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.Oncogene2020https://conductscience.org/library/papers/31519989PubMed
1924667376Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.Sci Signal2014https://conductscience.org/library/papers/24667376PubMed
2034084213HER3 expression and MEK activation in non-small-cell lung carcinoma.Lung Cancer Manag2021https://conductscience.org/library/papers/34084213PubMed

See all 149 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.

PMIDTitleJournalYearIn PapersSource
42449909Tracking Bone Loss in GLP-1RA Therapy: The Potential of the Deoxypyridinoline Urine Test.Diagnostics (Basel)2026https://conductscience.org/library/papers/42449909PubMed
41114412Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.Prz Menopauzalny2025https://conductscience.org/library/papers/41114412PubMed
40433388Antibody-drug conjugates as game changers in bladder cancer: current progress and future directions.Front Immunol2025https://conductscience.org/library/papers/40433388PubMed
40290122HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway.Genes Dis2025https://conductscience.org/library/papers/40290122PubMed
40123590Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment.Int J Mol Cell Med2025https://conductscience.org/library/papers/40123590PubMed
40108093Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability.Hum Cell2025https://conductscience.org/library/papers/40108093PubMed
40087402Emerging importance of HER3 in tumorigenesis and cancer therapy.Nat Rev Clin Oncol2025https://conductscience.org/library/papers/40087402PubMed
39984637Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth.Nat Nanotechnol2025https://conductscience.org/library/papers/39984637PubMed
39147936Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies.Clin Transl Oncol2025https://conductscience.org/library/papers/39147936PubMed
38473386Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.Cancers (Basel)2024https://conductscience.org/library/papers/38473386PubMed
38239350Targeting HER3 to overcome EGFR TKI resistance in NSCLC.Front Immunol2023https://conductscience.org/library/papers/38239350PubMed
38231075The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.Curr Med Chem2025https://conductscience.org/library/papers/38231075PubMed
38200149SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs.Acta Pharmacol Sin2024https://conductscience.org/library/papers/38200149PubMed
38023167Triple-negative breast cancer: from none to multiple therapeutic targets in two decades.Front Oncol2023https://conductscience.org/library/papers/38023167PubMed

Download CSV of cited by

Genes45

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
AREG374PubTator's text mininghttps://conductscience.org/library/genes/374NCBI Gene
AXL558PubTator's text mininghttps://conductscience.org/library/genes/558NCBI Gene
BAK1578PubTator's text mininghttps://conductscience.org/library/genes/578NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BTC685PubTator's text mininghttps://conductscience.org/library/genes/685NCBI Gene
EGF1950PubTator's text mininghttps://conductscience.org/library/genes/1950NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EPGN255324PubTator's text mininghttps://conductscience.org/library/genes/255324NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
ERBB42066PubTator's text mininghttps://conductscience.org/library/genes/2066NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
FGFR32261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
GAB12549PubTator's text mininghttps://conductscience.org/library/genes/2549NCBI Gene
GRB22885PubTator's text mininghttps://conductscience.org/library/genes/2885NCBI Gene

See all 45 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36551663

GET https://conductscience.org/api/papers/v1/36551663/references?page=2